Voya Investment Management LLC Reduces Holdings in ANI Pharmaceuticals, Inc. $ANIP

Voya Investment Management LLC lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 54.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,807 shares of the specialty pharmaceutical company’s stock after selling 8,089 shares during the quarter. Voya Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $624,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. grew its holdings in shares of ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the last quarter. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. Finally, Emerald Advisers LLC increased its position in shares of ANI Pharmaceuticals by 414.8% in the 2nd quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock valued at $82,000 after acquiring an additional 1,012 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the company. Guggenheim lifted their price target on ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. HC Wainwright increased their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Truist Financial raised their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday. Finally, JPMorgan Chase & Co. increased their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $102.14.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,622 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the sale, the senior vice president owned 58,564 shares in the company, valued at approximately $4,825,673.60. This trade represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Patrick D. Walsh sold 8,643 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the transaction, the director owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. This trade represents a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 28,001 shares of company stock worth $2,446,934. 11.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $78.94 on Friday. The firm has a market capitalization of $1.77 billion, a P/E ratio of 48.43 and a beta of 0.48. The stock has a 50-day simple moving average of $84.48 and a two-hundred day simple moving average of $82.49. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.74 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company’s revenue was up 53.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.